Tumor inhibition by enzalutamide in a xenograft model of ovarian cancer Journal Article
| Authors: | Park, B. Y.; Grisham, R. N.; den Hollander, B.; Thapi, D.; Berman, T.; de Stanchina, E.; Zhou, Q.; Iyer, G.; Aghajanian, C.; Spriggs, D. R. |
| Article Title: | Tumor inhibition by enzalutamide in a xenograft model of ovarian cancer |
| Abstract: | Objectives: To investigate the tumor-suppressive properties of enzalutamide in androgen-driven ovarian cancer. Methods: Mice were implanted subcutaneously with OVCAR-3 cells and treated with dihydrotestosterone in combination with enzalutamide or vehicle control. Tumor volumes were measured twice weekly until day 56. Results: Dihydrotestosterone exposure led to a significant increase in tumor growth, while concomitant treatment with enzalutamide led to significant reductions in tumor volume compared to the androgen-exposed groups. Conclusions: We present the first evidence that the second-generation anti-androgen enzalutamide may possess efficacy in the treatment of ovarian cancer, paving the way for the future clinical trials. © 2016 Taylor & Francis Group, LLC. |
| Keywords: | xenograft; androgen receptor; epithelial ovarian cancer; enzalutamide; ovcar-3 |
| Journal Title: | Cancer Investigation |
| Volume: | 34 |
| Issue: | 10 |
| ISSN: | 0735-7907 |
| Publisher: | Informa Healthcare |
| Date Published: | 2016-01-01 |
| Start Page: | 517 |
| End Page: | 520 |
| Language: | English |
| DOI: | 10.1080/07357907.2016.1242598 |
| PROVIDER: | scopus |
| PUBMED: | 27824515 |
| PMCID: | PMC5546102 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 3 January 2017 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
38Thapi -
254Zhou -
344Iyer -
170Grisham -
609Aghajanian -
325Spriggs -
346De Stanchina
Related MSK Work